|
|
Post by jlaw277 on Mar 4, 2019 14:41:42 GMT -5
MC mentioned dornase alfa (aka Pulmozyme by Genentech/Roche) in his most recent presentation at the Leerink conference ( link). In his discussion of the pipeline, he chose to highlight dornase right after discussing UTHR and RLS. It is a Bucket 1 opportunity and looks very similar to the trepostinil opportunity. Pulmozyme is an FDA approved inhaled drug that plays a part in the treatment of cystic fibrosis that appears to be quite cumbersome and complicated to take. It requires a compressor and nebulizer. Here are a few links from Genentech/Roche that show this to be the case: www.pulmozyme.com/patient/pulmozyme-dosing-nebulizer-use.htmlwww.pulmozyme.com/patient/resources/pulmozyme-cystic-fibrosis-faqs.htmlwww.gene.com/download/pdf/pulmozyme_IFU.pdfThis question in the FAQ stands out: How can I fit my Pulmozyme treatment into my daily routine?Finding the time and place to take your treatments, like Pulmozyme, isn’t always easy. No one is perfect. But having a routine that fits your lifestyle can help you stay in control and assist in your fight against cystic fibrosis.
2018 Global Sales for Pulmozyme were roughly $730 million with US Sales of roughly $500 million. ( link) It will be interesting to see what happens here because the company has a great road map (thanks to the TreT deal) towards finding a deal here. I could see Genentech/Roche cutting a similar deal to UTHR in an effort to maintain their market share and possibly renew patent protection. A low teens royalty would be $70-90 million a year plus upfront fees and milestone payments. This will be interesting to watch. |
|
|
|
Post by #NoMoreNeedles on Mar 4, 2019 14:45:06 GMT -5
Redeye to Basel, Switzerland!?
|
|
|
|
Post by sportsrancho on Mar 4, 2019 16:13:40 GMT -5
Awe....so it is Roche #Whispers
|
|
|
|
Post by louaboardalia on Mar 4, 2019 23:15:02 GMT -5
Your reference is to annual gross sales, not net revenue. MNKD's low teens royalty is based upon net revenue.
|
|
|
|
Post by jlaw277 on Mar 5, 2019 10:00:13 GMT -5
Your reference is to annual gross sales, not net revenue. MNKD's low teens royalty is based upon net revenue. Good point, although Roche has on average a 70% gross margin, so even if we consider a worse case scenario with regards to net sales, we are still talking very decent money. Mannkind just needs to keep hitting singles and doubles to set up for a possible home run. I am happy that they are pursuing something like dornase Alfa because I think there is a higher probability of near term success. |
|
|
|
Post by hellodolly on Mar 5, 2019 10:24:49 GMT -5
Your reference is to annual gross sales, not net revenue. MNKD's low teens royalty is based upon net revenue. Good point, although Roche has on average a 70% gross margin, so even if we consider a worse case scenario with regards to net sales, we are still talking very decent money. Mannkind just needs to keep hitting singles and doubles to set up for a possible home run. I am happy that they are pursuing something like dornase Alfa because I think there is a higher probability of near term success. Singles and doubles don't set up possible home runs but, they statistically produce a boatload of RBI's. I'll keep taking those runs (off hits) everyday, rather than hope or wait for the potential HR. But, your point is well taken and I get the context and spirit implied. I think if we can keep adding some doubles and singles, through the inclusion of new partnerships on inhaled drugs like dornase, WS will recognize MNKD's potential and reward them based on potential (like so many other biotechs) and not only on revenue. |
|
|
|
Post by harryx1 on Mar 5, 2019 13:45:32 GMT -5
I believe it would provide substantial lifestyle benefits to CF patients as TreT will to PAH patients. - Less time consuming - Faster administration - Less device maintenance - Disposable cartridges (no need for cleaning & filling) - Mobile, compact & no electricity required Watch the video on how Pulmozyme (Dornase Alfa) actually works. www.pulmozyme.com/patient/about-pulmozyme/how-does-pulmozyme-work.htmlI really hope that Dornase Alpha & Tobramycin are the next molecules to get partnerships. Along with a collaboration with the Cystic Fibrosis Foundation to further develop CF advancements like delivering the CFTR-encoded mRNA molecule or vector to the deep lungs. |
|
|
|
Post by jkendra on Oct 5, 2022 12:49:19 GMT -5
www.fiercepharma.com/pharma/change-top-roche-diagnostics-chief-schinecker-take-over-ceo-replacing-schwanChange at the top for Roche: Diagnostics chief Schinecker to take over as CEO replacing Schwan
By Kevin DunleavyJul 21, 2022 10:05am Leading Roche’s successful effort to develop COVID-19 test kits helped solidify Thomas Schinecker’s status as the company’s heir apparent to the CEO post. On Thursday, the Swiss pharma powerhouse made it official. On the same day that it reported its quarterly earnings, Roche said in a separate release that 47-year-old Schinecker, Ph.D.—the CEO of the company’s diagnostics division for the last three years—will take over effective on March 15 of next year, replacing Severin Schwan. Schwan, 54, who became one of the world’s youngest Big Pharma CEOs when he took over in 2008, will move to the chairman seat at Roche, replacing Chris Franz, who has held the position since 2014 and will not seek reelection to the board. “It is now the right time for a change in leadership,” Franz said in the announcement. Schinecker’s star continued to rise during the pandemic. Last year, Roche’s testing sales grew 29% to 17.8 billion Swiss francs ($19.4 billion), with COVID diagnostics accounting for roughly a quarter of the total. The performance helped Roche recover from its decline in oncology, especially in the United States where biosimilars have dented sales for longtime blockbusters Rituxan, Avastin and Herceptin. Schwan credited Schinecker’s rise to his “fantastic, outstanding track record,” during a call with reporters. Schwan added that the change has been in the works as part of Roche’s “long-term planning and continuity.” Schinecker’s takeover will come in his 20th year with the company, while it will be Schwan’s 30th year at Roche. Schwan took the same route as Schinecker, also serving as diagnostics chief before moving up to the CEO role. Schwan was rewarded as well for guiding the company “confidently and successfully through challenging times,” Andre Hoffman, vice president of Roche’s board, said in the release. One of Schwan's first successes was to acquire California biotech Genentech for $46.8 billion. Later, he also helped Roche diversify from the dependence the lucrative oncology products from Genentech brought as the company has thrived behind hemophilia drug Hemlibra and multiple sclerosis med Ocrevus. In November of last year, with the company’s stock price trading at an all-time high on the SIX Swiss Exchange, Roche bought back its 33% voting stake from Novartis for roughly $20.7 billion.
|
|
|
|
Post by cppoly on Oct 6, 2022 10:01:36 GMT -5
What's the significance of this? Thanks
|
|
|
|
Post by peppy on Oct 6, 2022 10:09:26 GMT -5
What's the significance of this? Thanks dornase alfa (aka Pulmozyme by Genentech/Roche)  |
|
|
|
Post by Clement on Oct 6, 2022 10:55:54 GMT -5
My foggy memory seems to recall MC talking about de-emphasizing dornase alpha for the time being. Maybe because we would not want to take on further trials without a partner? I tried searching for this and came up with nothing. Does anyone remember this?
|
|
|
|
Post by jkendra on Oct 26, 2022 10:48:50 GMT -5
www.fiercepharma.com/pharma/time-do-time-crime-former-genentech-staffers-sentenced-six-months-each-trade-secrets-caseIn the high-profile case, government prosecutors said the couple stole confidential intellectual property related to Genetech’s top-sellers Rituxan, Herceptin, and Avastin, as well as cystic fibrosis inhalation Pulmozyme. The two then passed the secret info to Taiwanese firm JHL Biotech (now Eden Biologics), to aid in its development of copycats, the suit said. The Lams weren’t the only schemers in the game, but compared to the other conspirators, the Lams got off relatively easy. Two co-founders of JHL, ex-CEO Racho Jordanov and ex-COO Rose Lin, were each sentenced to one year and one day in prison. Those two will be on suspended release for 3 years after serving their sentence. The scheme started before JHL Biotech was founded and continued through 2019, the government said. At JHL, the company specifically recruited former Genentech staffers to steal confidential information. While JHL didn't use all of the stolen documents, the practice was “tolerated” and no efforts were made to discourage staffers at JHL from using the information, allowing the company to cut corners, according to authorities. Xanthe Lam came into play when Lin arranged for her to covertly work as head of formulation at JHL, knowing she was simultaneously working full-time at Genentech. Lin paid her through Allen Lam, allowing Xanthe to work without entering a direct contract. Further, others at JHL maintained contact with Xanthe through her husband’s email address. The Lams will be back in court on December 5, 2023, for a progress report. Payment for their fines is due no later than 30 days after the entry of judgment, which is dated October 18.
|
|
|
|
Post by JEvans on Oct 26, 2022 13:50:40 GMT -5
www.fiercepharma.com/pharma/time-do-time-crime-former-genentech-staffers-sentenced-six-months-each-trade-secrets-caseIn the high-profile case, government prosecutors said the couple stole confidential intellectual property related to Genetech’s top-sellers Rituxan, Herceptin, and Avastin, as well as cystic fibrosis inhalation Pulmozyme. The two then passed the secret info to Taiwanese firm JHL Biotech (now Eden Biologics), to aid in its development of copycats, the suit said. The Lams weren’t the only schemers in the game, but compared to the other conspirators, the Lams got off relatively easy. Two co-founders of JHL, ex-CEO Racho Jordanov and ex-COO Rose Lin, were each sentenced to one year and one day in prison. Those two will be on suspended release for 3 years after serving their sentence. The scheme started before JHL Biotech was founded and continued through 2019, the government said. At JHL, the company specifically recruited former Genentech staffers to steal confidential information. While JHL didn't use all of the stolen documents, the practice was “tolerated” and no efforts were made to discourage staffers at JHL from using the information, allowing the company to cut corners, according to authorities. Xanthe Lam came into play when Lin arranged for her to covertly work as head of formulation at JHL, knowing she was simultaneously working full-time at Genentech. Lin paid her through Allen Lam, allowing Xanthe to work without entering a direct contract. Further, others at JHL maintained contact with Xanthe through her husband’s email address. The Lams will be back in court on December 5, 2023, for a progress report. Payment for their fines is due no later than 30 days after the entry of judgment, which is dated October 18. What does this have to do with Mannkind ? |
|
